Sage Journals: Discover world-class research

Abstract

The data from different studies suggest a bacterial role in cancer genesis/progression, often modulating the local immune response. This is particularly so at the mucosal level where the bacterial presence is strong and the immune system is highly reactive. The epithelial surfaces of the body, such as the skin and mucosa, are colonized by a vast number of microorganisms, which represent the so-called normal microbiome. Normally the microbiome does not cause a proinflammatory response because the immune system has developed different strategies for the tolerance of commensal bacteria, but when these mechanisms are impaired or new pathogenic bacteria are introduced into this balanced system, the immune system reacts to the microbiome and can trigger tumor growth in the intestine. In this review, we discuss the potential role of the bacterial microbiome in carcinogenesis, focusing on the direct and indirect immune adaptive mechanisms, that the bacteria can modulate in different ways.

Keywords

adaptive immune response bacteria colorectal cancer microbiome Th17

Introduction

The involvement of infectious elements in the cancer etiology has recently polarized the attention of many researchers. In the past, in 1890, the Scottish pathologist William Russell [Russell, 1890] reported circumstantial evidence for the bacterial cause of cancer. Actually, the data from different studies have strengthened the theory proposed by Russell suggesting a bacteria role in carcinogenesis and cancer progression, often interfering with and modulating the local immune response [Shahanavaj et al. 2015]. This is especially true at the mucosal level, where the bacterial presence is strong and the immune system is highly reactive. Actually, the epithelial surfaces of the body, such as the skin and the mucosa, are colonized by a vast number of microorganisms, which represent the so-called normal microbiome (Figure 1).

Figure 1.

Different sorts of bacteria living in different places in and on the body.

The human microbiome is composed of organisms belonging to the domains of the Bacteria, Archaea, Eukarya and their viruses. Most of the commensal bacteria are symbiotic, however, after translocation through the mucosa or under specific conditions (e.g. immunodeficiency), commensal bacteria can cause pathology.

The intestinal mucosa is the largest surface of the body that is constantly exposed to dietary and bacterial antigens. The gastrointestinal tract of mammals harbors a bacterial community containing trillions of members, including thousands of different species. There are more than 50 bacterial phyla on Earth, but the human gut-associated microbiome is dominated by four main phyla: Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria [Eckburg et al. 2005; Mahowald et al. 2009] (Figure 1). A wide proportion, about 70%, of the human microbiome is composed of bacteria that cannot be cultivated by current microbiological methods. The traditional culture-based methods capture less than 30%, of our bacterial microbiome [Fraher et al. 2012]. However, today, genomic next-generation sequencing analysis has been essential in defining and understanding the bacterial microbiome and metagenome, and their key role in metabolism, inflammation and cancer progression [Kau et al. 2011; Human Microbiome Project Consortium, 2012].

The human microbiome is essential to body physiology, as it could produce an enormous quantity of molecules able to interact with the host. In particular, the bacteria of the gut microbiome represent a natural defense against colonization with pathogens and furthermore, they break down indigestible dietary components (e.g. vegetal polysaccharides) [Sonnenburg et al. 2004]. The bacteria communities are separated from the internal gut milieu by a single layer of epithelial cells, which not only is a physical and chemical barrier, but also balances the crosstalk between the external environment and immune host system. In addition, the epithelial surfaces have evolved protective mechanisms to counteract microorganism invasion. Effective innate and adaptive immune responses protect the mucosa and the internal environment of the human body. Almost 80% of the immunologically active cells belong to the mucosal-associated immune system. Most of these cells are present in the gastrointestinal tract, where immunogenic agents, such as food and components of the bacterial flora, are at the highest level with respect to other parts of the body.

Normally the microbiome does not cause a proinflammatory response because the immune system has developed various mechanisms to tolerate the commensal bacteria and preserve the homeostasis, but when these mechanisms are impaired or new pathogenic bacteria are introduced into this balanced system, the immune system reacts to the microbiome and can trigger tumor growth in the intestine [Schwabe and Jobin, 2013].

In this review we discuss the potential role of the bacterial microbiome in carcinogenesis, focusing on the direct and indirect immune adaptive mechanisms that the bacteria can modulate promoting, supporting or counteracting cancer development.

Microbiome’s role in tumor development

Recent evidence suggests that human disease is attributable not only to a single bacteria but also to global changes in the host microbiome [Turnbaugh et al. 2006; Smith et al. 2013]. Different studies in germfree animals associated with bacteria have revealed evidence for tumor-promoting effects of the microbiome in spontaneous and genetically induced cancers in several organs, including skin, colon, liver, breast and lungs [Dapito et al. 2012; Sacksteder, 1976; Dove et al. 1997].There are also data showing the contrary view that gut microbiota have a central role in limiting chemically induced injury and proliferative responses that lead to tumor development in germ-free animals [Zhan et al. 2013]. In 1975, Reddy and colleagues first linked the gut microbiome to intestinal cancer development, establishing that only 20% of genetically modified germ-free rodents develop chemically induced colon cancer. In contrast, the tumor incidence in conventional rats with a normal microbiome was about 90% with several neoplasms [Reddy et al. 1975]. Vannucci and colleagues confirmed these data showing that germ-free rats, compared with genotypically similar animals with a normal microbiome, develop smaller tumors, as spontaneously as after chemically induced carcinogenesis [Vannucci et al. 2008]. Moreover, in colitis-associated cancer and adenomatous polyposis coli (APC)-related colorectal cancer, germ-free mice display decreased tumor formation and less oncogenic mutations [Rakoff-Nahoum and Medzhitov, 2008]. In addition, antibiotics depletion of the gut microbiota in mice reduces cancer development in the colon and the liver [Dapito et al. 2012; Yoshimoto et al. 2013; Chen et al. 2008; Klimesova et al. 2013] as does the eradication of specific pathogens in humans and in mice [Lee et al. 2008; Wong et al. 2004].

All these studies provide compelling evidence for the microbiome’s role in tumor growth. Probably, the germ-free rats can develop a more active anticancer immune response in the absence of the physiological inflammation induced by the presence of a commensal microbiome. For this purpose, Sears and Pardoll [Sears and Pardoll, 2011] suggest that ‘alpha bugs’ (certain microbiome members possessing unique virulence traits), such as enterotoxigenic Bacteroides fragilis (ETBF), are directly pro-oncogenic and able to remold the mucosal immune response and colonic bacterial-removing species that protect against cancer thus promoting cancer growth.

The ‘bacterial driver–passenger’ model was first suggested by Tjalsma and colleagues [Tjalsma et al. 2012] to describe the microbial involvement in the development of colorectal cancer. According to this model, distinct indigenous intestinal bacteria, called ‘driver bacteria’ would create DNA damage and drive genome instability to initiate the first phases of cancer progression. As a consequence, the bacterial drivers (alpha bugs and their helpers) are gradually replaced by gut commensals with either tumor-promoting or tumor-suppressing properties (bacterial passengers). This model proposes that disease progression causes changes in the microenvironment as a result of the increasing tumor, resulting in a reformed selective pressure on the microbial community.

The importance of the human microbiome in host health and disease is also described by the ‘keystone pathogen’ hypothesis. The term ‘keystone’ has been introduced in the ecological literature to characterize species whose effects on their communities are disproportionately large relative to their abundance and which are thought to form the ‘keystone’ of the community’s structure. This hypothesis supposes that some low-abundance microbial pathogens can orchestrate inflammatory disease by remodeling a normally benign microbiome into a dysbiotic one [Hajishengallis et al 2012].

Finally, inflammatory responses elicited by bacteria were demonstrated to be able to enhance cancer progression [Fukata and Abreu, 2008]. Some bacteria are able to induce alterations of mucosal permeability, facilitating the translocation of bacteria and bacterial toxins (e.g. lipopolysaccharide). Inflammation contributes to the development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. An increasing number of studies demonstrated the role of inflammation in establishing conditions that can deeply alter local immune responses and thus, tissue homeostasis. In particular, it is well documented that inflammatory mediators [such as interleukin (IL)-1, tumor necrosis factor-α (TNF-α), IL-8, nitric oxide or prostaglandin-2 derivatives] and molecules of the inflammatory pathways, are involved in a progressive interplay between the immune cells and tissue cells undergoing transformation [Mantovani et al. 2008].

The role of adaptive immune response in cancer progression

Vertebrates have evolved the machinery of adaptive immunity to counteract the pathogens that evade or overcome the innate immune defense. Normally the components of the adaptive immune system are silent; however, when activated, these components ‘adapt’ to the presence of infectious agents by activating, proliferating, and creating potent mechanisms to neutralize or eliminate the microbes. However, some of these responses can be protumorigenic.

There are two types of adaptive immune responses: humoral immunity, mediated by antibodies produced by B cells, and cell-mediated immunity, mediated by T cells, that are divided into two subsets: the CD8⁺ (CTL) and the CD4⁺ or T helper (Th). An effective antitumor immune response requires the involvement of both CD4⁺ and CD8⁺ T cells [Schreiber et al. 2011]. The role of CD4⁺ T cells in antitumor immunity has recently been extensively studied in preclinical animal models and in clinical cancer patients. CD4⁺ T cells are critical for priming tumor-specific CD8⁺ T cells and for the secondary expansion and memory of CD8⁺ T cells [Janssen et al. 2003]. However, the discovery of regulatory T cells (Treg) and Th17 cells not only updated the classical Th1/Th2 paradigm of Th cell differentiation, but also markedly revolutionized the concept regarding the role of CD4⁺ T cells in antitumor immunity [Wang et al. 2012]. It has been demonstrated that tumor-infiltrating Tregs induce an immunosuppressive microenvironment, preventing an effective antitumor immunity and becomes a major obstacle to the success of anticancer immunotherapy [Curiel, 2008]. Furthermore, the functional contribution of human Th17 cells to tumor immunity remains controversial since both protumor and antitumor effects have been observed varied among tumor types [Wilke et al. 2011].

In addition to protection against cancer cells and pathogens, acquired immunity is essential for the establishment of complex bacterial communities in the gut.

Mechanisms of microbiome-driven carcinogenesis substantially differ between organs and the microbiome can modulate tumor development through direct and indirect actions. The microbial products can directly promote tumor growth or indirectly, that is the bacteria per se are not able to promote tumor progression unless they interact with the immune system. Finally, it is also possible that deficiencies in specific mechanisms of the immune response allow the expansion of certain bacteria, which activate a protumorigenic immune response.

The following paragraphs describe how the microbiota influence the adaptive immune response and, in turn, promote or counteract tumor development.

Direct responsibility of bacterial factors in cancerogenesis

Gastric cancer represents the most studied example of carcinogenesis closely related to infection by a specific bacterial pathogen, Helicobacter pylori [Lofgren et al. 2011; Peek and Blaser, 2002; Fox and Wang, 2007]. H. pylori, identified as a carcinogenic pathogen [Parkin et al. 2002], colonizes the human stomach and duodenum, leading to the sequential development of gastritis, gastric ulcer, atrophy and finally gastric cancer [Fox and Wang, 2007; Amedei et al. 2014]. H. pylori infection contributes to global cancer mortality with gastric cancer occurring in 1–3% of infected individuals [Fox and Wang, 2007]. H. pylori producing gastric atrophy and hypochlorhydria, renders the stomach susceptible to bacterial overgrowth, and subsequently increased bacterial conversion of dietary nitrates into carcinogens [Lofgren et al. 2011].

In addition, H. pylori infection is associated with the lymphoid hyperplasia of gastric mucosa that represents a preneoplastic condition of the mucosa-associated lymphoid tissue (MALT), which may evolve to a B-cell lymphoma [Munari et al 2011], where the anti-H. pylori immune response, seems to have a key role, in particular the macrophages and the Th lymphocytes [Amedei et al. 2014]. Recently, Munari and colleagues showed how H. pylori infection induces a Th17 response [Munari et al 2014]. They studied the expression of cytokines in infected patients with chronic gastritis focusing on a role for B-cell activating factor (BAFF; CD257) in promoting Th17 differentiation. High levels of IL-17 and BAFF were present in gastric mucosa of H. pylori-positive patients with chronic gastritis and BAFF was especially abundant in macrophages and monocytes. Exposing monocytes to BAFF triggered reactive oxygen species (ROS) accumulation and also resulted in the production of IL-6, IL-1b, IL-23 and TGF-β. Monocytes exposed to H. pylori produced pro-Th17 cytokines and contribute directly to drive the gastric milieu in chronic gastritis. H. pylori affects the tumor microenvironment by increasing the IL-17A secretion and high levels of serum IL-23A in gastric cancer patients correlated with poor prognosis.

Recently, we have investigated the effector functions of gastric tumor-inﬁltrating lymphocytes speciﬁc for the H. pylori-secreted peptidyl prolyl cis, trans-isomerase (HP0175) [Amedei et al. 2014]. Tumor-inﬁltrating lymphocytes from patients with gastric adenocarcinoma, stimulated in vitro with HP0175, produced high levels of IL-17 and IL-21. T-cell clones derived from these populations were then tested for cytolytic ability and their ability to provide help to monocytes. While the cytolytic ability was poor, all of the Hp0175-speciﬁc Th17 clones were found to induce matrix metalloproteinase (MMP)-2 and MMP-9 production by monocytes. We hypothesized that HP0175-speciﬁc Th17 cells in the tumor drive the production of MMPs that promote angiogenesis and inﬂammation through IL-21 production.

Another example of tumors caused by specific bacterial pathogens is the gallbladder cancer associated with chronic Salmonella enterica subsp., Enterica serovar Typhi and Enterica serovar Paratyphi infections [Caygill et al. 1994; Welton et al. 1979].

Both Gallbladder cancer and gastric MALT are examples of tumors triggered by adaptive immune responses against specific pathogens [Caygill et al. 1994; Wotherspoon et al 1993]. In addition, some lymphomas are associated with bacterial infections, such as Campylobacter jejuni, Borrelia burgdorferi and Chlamydia psittaci, and after antibiotic treatment a regression has been observed [Lecuit and Lortholary, 2004; Ferreri et al. 2012].

Fusobacterium nucleatum has recently been shown to directly promote intestinal tumorigenesis when its adhensin, FadA, binds to E-cadherin on epithelial cells and activates b-catenin signaling to promote epithelial cell proliferation [Rubinstein et al. 2013; Kostic et al. 2013]. Additional bacterial pathogens such as Enterococcus faecalis, enterotoxigenic Bacteroides fragilis and Helicobacter hepaticus promote cancer in animal models, but there is no clear epidemiological link to human carcinogenesis.

Finally, the microbiome has the capacity to directly modulate tumorigenesis through the production of specific toxins, such as genotoxins, that induce DNA damage responses, or tumor-promoting metabolites. For example, different bacterial toxins such as cytolethal distending toxin (CDT), cytotoxic necrotizing factor 1,B. fragilis toxin and colibactin, affect crucial cellular processes, implicated in tumorigenesis, and especially the responses to DNA damage [Arthur et al. 2012; Wu et al. 2009]. Microorganisms relevant to colorectal, gastric and gallbladder cancer (e.g. E. coli, Helicobacter spp. and S. Typhi) are CDT producers [Smith et al. 2013].

Various bacterial-derived metabolites, for instance hydrogen sulphide and superoxide radicals, may cause genomic instability [Carbonero et al. 2012; Huycke and Gaskins, 2004]. Enterococcus faecalis can generate large amounts of extracellular superoxide, which causes double-strand DNA breaks and chromosome instability leading to the development of colorectal cancer in mice [Wang and Huycke, 2007; Wang et al. 2012]

Antibacteria-specific immune response and tumor starting

Host-derived immune and inflammatory responses are an important driving force that shape the microbial community composition and, when altered, may contribute to dysbiosis. Some members of the microbiota alter the adaptive immune response and, in turn, promote cancer growth. One of the main instruments by which the microbiome can indirectly promote tumor growth are the Th17 cells. Commensal microbiota actively shape intestinal T-cell responses to promote homeostasis. For example, Th17 cells control microbial invasion in the gut, but specific compensatory mechanisms are required to regulate in turn the Th17 cells.

In the mammalian intestine the commensal bacteria induce IL-1β production to maintain a basal level of Th17 cells in the lamina propria under physiological conditions [Shaw et al 2012]. However, in response to pathogenic extracellular bacterial or fungal infections, large numbers of naive Th cells differentiate into Th17 under the influence of IL-1β, IL-6, IL-23 or TGFβ in mucosal surfaces of the gut and respiratory tract [Ouyang et al. 2008]. If those mechanisms are impaired, Th17 cells become pathogenic and can induce autoimmune disease and chronic inflammation. When stimulated with IL-6 and TGF-β, the antigen-activated CD4⁺ T cells upregulate the transcription factor, retinoic acid receptor-related orphan receptor gamma t (RORγt) and secrete Th17-specific cytokines such as IL-17 and IL-22 [Korn et al. 2009]. Usually, the CD4⁺ T cells that express RORγt increase tight junction formation and stimulate the secretion of microbicidal protein, contributing to the barrier function of the intestinal epithelium but they can have also a protumorigenic role [Korn et al. 2009].

As stated previously, compelling evidence suggests that Th17 cells and their cytokines have a strong tumorigenic potential, but the functional role of Th17 in cancer is ambiguous, it appears to have protumorigenic and antitumorigenic activities and the responses seem to depend on the cancer type [Grivennikov et al. 2012; Muranski et al. 2008; Murugaiyan and Saha, 2009]. In addition to IL-17A production, Th17 cells can secrete IL-17F, IL-21, IL-22, interferon (IFN)-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) [Zheng et al. 2008; Mitsdoerffer et al. 2010].

Th17 responses and mainly the IL-17 action itself, were initially thought to be proangiogenic, proinvasive and cancer growth promoting [Numasaki et al. 2003]. In a mouse model, the Th17 cells are able to promote colorectal cancer development, induced by colon inflammation [Wu et al. 2009]. Experiments with genetically predisposed mice (APCmin/+) crossed with IL-17A-deficient mice point out drastic impairment in intestinal tumorigenesis [Chae et al. 2010]. In addition, it has been shown that APCmin/+ mice that cannot respond to IL-17 develop fewer tumors in the colon [Grivennikov et al. 2012].

In humans, the role of Th17 cells has been investigated in patients with different cancer types, including ovarian cancer, prostate cancer, and many others [Yang et al. 2009; Horlock et al. 2009; Zhang et al. 2008a, 2009; Wang et al. 2008; Dhodapkar et al. 2008; Charles et al. 2009; Derhovanessian et al. 2009; Inozume et al. 2009; Koyama et al. 2008]. Most of these studies have examined Th17 cells in peripheral blood, but Th17 cells may be induced in or recruited to the cancer microenvironment [Kryczek et al. 2007, 2009].

Above, we have affirmed that the intestinal microbiota promote colorectal cancer development. More direct proof for a role of bacterially stimulated tumor growth via Th17 cells comes from studies of enterotoxigenic Bacteroides fragilis. This human colonic bacterium secretes B. fragilis toxin (BFT) that causes human inflammatory diarrhea. Several mouse models, predisposed to develop gut tumors, indicate that between colonization of B. fragilis and nontoxigenic B. fragilis, only the first triggers colitis and induces colonic tumors [Wu et al. 2009]. In particular, B. fragilis induces selective colonic signal transducer and transcription-3 (STAT3) activation with colitis characterized by a selective Th17 response. Antibody-mediated blockade of IL-17, as well as the IL-23 receptor, inhibits B. fragilis-induced colitis, colonic hyperplasia and tumor formation. These results show a STAT3- and Th17-dependent pathway of inflammation-induced cancer by a common human commensal bacterium, providing a new mechanistic insight into human colon carcinogenesis. In other words, these data support the role of Th17 cells and their cytokines (IL-17 and IL-22) in intestinal carcinogenesis.

Further experimental conditions have confirmed the ability of the microbiome to modulate the Th17 response. The Th17 response upon contact with specific bacteria, stimulates the expansion of neutrophil cells, required for the clearance of invading bacteria [Aujla et al. 2007; Blaschitz and Raffatellu, 2010]. The Th17 response is important for protection against mucosal pathogens like Klebsiella pneumonia and Salmonella typhimurium. Mice deficient in Th17 cytokines show a serious pathology during infection with Salmonella or C. rodentium, with increased translocation of bacteria into lymph nodes. [Raffatellu et al. 2008].

Other bacteria species capable of activating Th17 are the segmented filamentous bacteria (SFB), belonging to nonculturable Clostridia-related species, and flagellin-positive bacteria. These bacteria interact with the epithelial cells in the host epithelial barrier promoting chronic inflammation, mediated by IL-17 and IL-22 release, which likely favors the development of intestinal cancer.

Recently, SFB has been shown to support the generation of Th17 cells [Suzuki et al. 2004] and only in the animals colonized with SFB, were found strong Th17 responses [Gaboriau-Routhiau et al. 2009; Korn et al. 2009; Reigstad and Backhed, 2010; Ivanov et al. 2009]. Moreover SFB-induced Th17 cells exacerbate autoimmunity, such as arthritis, that could be tempered by treating mice with certain antibiotics that reduced Th17 cells [Kosiewicz et al. 2011].

Based on such interesting data, some investigators became motivated to target the microbiome in order to enhance Th17 and CD8⁺ T-cell responses against cancer cells [Gajewski et al. 2013].

As reported previously, Th17 cells produce other cytokines such as IL-22, which has been linked to intestinal tumorigenesis in murine models [Kirchberger et al. 2013; Huber et al. 2012]. IL-22BP (IL-22 R) is regulated by the inflammasome and modulates tumorigenesis in the intestine and in human colon cancer [Jiang et al. 2013]. IL-22 is related to the development of human colorectal cancer by STAT3 activation. A procarcinogenic rule for IL-22 via the STAT3 pathway, was previously shown in several extracolonic cancers such as hepatocellular carcinoma and non-small cell lung cancer [Zhang et al. 2008b; Jiang et al. 2011]. Little is known about the IL-22 role in colorectal cancer, although polymorphisms in IL-22 were shown to be associated with an increased risk for cancer development [Thompson et al. 2010]. Furthermore, IL-22 in conjunction with IFN-γ can induce inducible nitric oxide synthase (iNOS) production and procarcinogenic nitric oxygen species in human colon carcinoma cell lines [Ziesché et al. 2007]

Finally, the cytokine IL-23 is produced by myeloid cells in response to different microbiome molecules, such as flagellin [Kinnebrew et al. 2012]. IL-23 has the ability to promote Th17-type responses characterized by the induction of the cytokines IL-17 and IL-22 [Liang et al. 2006]. IL-23 was found to be increased in human colon adenocarcinoma and, through induction of proinflammatory responses, promotes tumor growth [Langowski et al. 2006].

Antitumorigenic impact of microbiome

Although most of the studies show tumor-promoting activity of the bacterial commensal flora, antitumor effects have also been reported. In the past, antitumor effects were observed in patients with sarcomas, after the injection of heat killed bacteria or bacterial infections (termed Coley’s toxin) [Starnes, 1992]. Subsequent studies assign these antitumor effects to specific bacterial components as NOD-like receptor (NLR) agonists and Toll-like receptor (TLR) agonists. The activation of innate immunity can convert cancer tolerance into an anticancer immune response [Garaude et al. 2012].

In addition, murine studies described an effective immune role in tumor surveillance and in the inhibition of proliferation and metastasis, which results in the cancer regression [Muranski et al. 2008; Kryczek et al. 2009; Martin-Orozco et al. 2009].

An anticancer microbiome-mediated effect was noted in hematopoietic tumors, through the Th17 response. In mouse models, the alkylating agent, cyclophosphamide, alters the microbiome composition, inducing dysbiosis in the small intestine and inducing the translocation of selected species of Gram⁺ bacteria into secondary lymphoid organs. These bacteria stimulate the generation of a specific subset of ‘pathogenic’ Th17 cells and memory Th1 immune responses, which result in a potent cancer-suppressive Th17 response [Viaud et al. 2013].

In addition, in a recent study [Amedei et al. 2013], it was demonstrated that Th17 cells have a specific antitumor effector function in patients with pancreatic cancer, and that there are decreased levels of these cells in cancer tissue compared to healthy mucosa. These results suggest that the gut microbiome can help shape the anticancer immune response.

In other words, although some bacteria are able to induce Th17 cells, others could promote control of Th17 cells, limiting cancer development. Lactobacillus, Bifidobacteria, and Clostridium can induce Foxp3⁺ Treg cells, a specific subset of regulatory T cells in the intestine [Honda and Littman, 2012]. These Foxp3⁺ Treg cells, through IL-10 secretion, can control the production of IL-17A and the proliferation of Th17 cells [Huber et al. 2011]. These interactions can have an anti-tumorigenic activity in the intestine. It is still not clear if this is due to the suppression of Th17 pro-tumorigenic activity, but Foxp3⁺ Treg cells can actively block intestinal tumor growth through IL-10 secretion [Erdman et al. 2003; Erdman et al. 2005].

Also, the Bacteroides species have been shown to have immunomodulatory effects. In particular Bacteroides fragilis releases polysaccharide A (PSA), that seems to block intestinal inflammation. The colonization of mice with B. fragilis resulted in the suppression of a proinflammatory Th17 reaction and this modulation could be attributed to PSA because B. fragilis lacking PSA was unable to suppress Th17 response, and also failed to persistently colonize the intestine [Round et al. 2011].

Finally, a selected mixture of Clostridia strains, recently identified from the human microbiome, is found able to attenuate disease in preclinical models of colitis through the induction of Tregs [Atarashi et al. 2008], revealing a potential antitumorigenic role. These results suggest that therapeutic colonization with specific strains of human-associated bacteria may have the potential to reduce tumorigenesis.

In conclusion, it is plausible that the integration of such multiple signals through their cumulative effects on specific commensal microbial populations and the various immune arms will result in context-specific effects on cancer development, establishing the microbiome as a critical hub integrating host and environmental signals, that are implicated in tumor formation or suppression.

Conclusion

The growing awareness of the importance of the gut microbiome in health and diseases and recognition of the host–microbe mutualism at the immunological and metabolic levels become important for a better understanding of several pathologies, especially cancer, a plague of our century.

Multiple lines of evidence support the notion that the microbiome shapes the immune system and indirectly modulates the development of tumors through the immune system in different organs. A positive modulation of the composition and metabolic activity of the gut microbiota might represent an interesting approach to reduce the risk of carcinogenesis and cancer development.

Today, finding new methods to selectively manipulate the microbiome in order to stop tumor initiation and progression represents an exciting challenge. In the near future, high quality mechanistic experimental studies and interventional human studies might provide the scientific premise for the clinical use of probiotics for the therapy of cancer and other multifactorial human diseases. We need a better understanding of the mechanisms whereby altered immunity shapes microbiome composition and determines which microbes are present to embrace us with their metabolites.

Footnotes

Funding

This work was supported by grants from the regional contribution of “the Programma Attuativo Regionale (Toscana) funded by FAS (now FSC), the Italian Ministry of University and Research and the Foundation ‘Ente Cassa di Risparmio di Firenze’.

Conflict of interest statement

The authors declare no conflict of interest in preparing this article.

References

Amedei

Munari

Bella

Niccolai

Benagiano

Bencini

. (2014) Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inﬂammation in gastric adenocarcinoma. Intern Emerg Med 9: 303–309.

Amedei

Niccolai

Benagiano

Della Bella

Cianchi

Bechi

. (2013) Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 62: 1249–1260.

Arthur

Perez-Chanona

Mühlbauer

Tomkovich

Uronis

Fan

. (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338: 120–123.

Atarashi

Nishimura

Shima

Umesaki

Yamamoto

Onoue

. (2008) ATP drives lamina propria T(H)17 cell differentiation. Nature 455: 808–812.

Aujla

Dubin

Kolls

(2007) Th17 cells and mucosal host defense. Semin Immunol 19: 377–382.

Blaschitz

Raffatellu

(2010) Th17 cytokines and the gut mucosal barrier. J Clin Immunol 30: 196–203.

Carbonero

Benefiel

Alizadeh-Ghamsari

Gaskins

(2012) Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol 3: 448.

Caygill

Hill

Braddick

Sharp

(1994) Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 343: 83–84.

Chae

Gibson

Zelterman

Hao

Henegariu

Bothwell

(2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 107: 5540–5544.

10.

Charles

Kulbe

Soper

Escorcio-Correia

Lawrence

Schultheis

. (2009) The tumour-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans.J Clin Invest 119: 3011–3023.

11.

Chen

Shaw

Redondo

Nunez

(2008) The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68: 10060–10067.

12.

Curiel

(2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241–246.

13.

Dapito

Mencin

Gwak

Pradere

Jang

Mederacke

. (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21: 504–516.

14.

Derhovanessian

Adams

Hähnel

Groeger

Pandha

Ward

. (2009) Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125: 1372–1379.

15.

Dhodapkar

Barbuto

Matthews

Kukreja

Mazumder

Vesole

. (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17–1 cells) enriched in the bone marrow of patients with myeloma. Blood 112: 2878–2885.

16.

Dove

Clipson

Gould

Luongo

Marshall

Moser

. (1997) Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 57: 812–814.

17.

Eckburg

Bik

Bernstein

Purdom

Dethlefsen

Sargent

. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635–1638.

18.

Erdman

Rao

Poutahidis

Ihrig

Feng

. (2003) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63: 6042–6050.

19.

Erdman

Sohn

Rao

Nambiar

Fox

. (2005) CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65: 3998–4004.

20.

Ferreri

Govi

Pasini

Mappa

Bertoni

Zaja

. (2012) Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 30: 2988–2994.

21.

Fraher

O’Toole

Quigley

(2012) Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 9: 312–322.

22.

Fox

Wang

(2007) Inflammation, atrophy, and gastric cancer. J Clin Invest 117: 60–69.

23.

Fukata

Abreu

(2008) Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27: 234–243.

24.

Gaboriau-Routhiau

Rakotobe

Lécuyer

Mulder

Lan

Bridonneau

. (2009)The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31: 677–689

25.

Gajewski

Schreiber

(2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14: 1014–1022.

26.

Garaude

Kent

van Rooijen

Blander

(2012) Simultaneous targeting of Toll- and NOD-like receptors induces effective tumor-specific immune responses. Sci Transl Med 4: 120ra16.

27.

Grivennikov

Wang

Mucida

Stewart

Schnabl

Jauch

. (2012) Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491: 254–258.

28.

Hajishengallis

Darveau

Curtis

(2012) The keystone-pathogen hypothesis. Nat Rev Microbiol 10: 717–725.

29.

Honda

Littman

(2012) The microbiome in infectious disease and inflammation. Annu Rev Immunol 30: 759–795.

30.

Horlock

Stott

Dyson

Morishita

Coombes

Savage

. (2009) The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100: 1061–1067.

31.

Huber

Gagliani

Esplugues

O’Connor

Huber

Chaudhry

. (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34: 554–565.

32.

Huber

Gagliani

Zenewicz

Huber

Bosurgi

. (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491:259–263.

33.

Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. Nature 486: 207–214.

34.

Huycke

Gaskins

(2004) Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med (Maywood) 229: 586–597.

35.

Inozume

Hanada

Wang

Yang

(2009) IL-17 secreted by tumour reactive T cells induces IL-8 release by human renal cancer cells.J Immunother 32: 109–117.

36.

Ivanov

Atarashi

Manel

Brodie

Shima

Karaoz

. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485–498.

37.

Janssen

Lemmens

Wolfe

Christen

von Herrath

Schoenberger

(2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852–856.

38.

Jiang

Tan

Deng

Chen

Xia

Gao

. (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54: 900–909.

39.

Jiang

Wang

Deng

Hou

Shi

Yao

. (2013) IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 13: 59.

40.

Kau

Ahern

Griffin

Goodman

Gordon

(2011) Human nutrition, the gut microbiome and the immune system. Nature 474: 327–336.

41.

Kinnebrew

Buffie

Diehl

Zenewicz

Leiner

Hohl

. (2012) Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 36: 276–287.

42.

Kirchberger

Royston

Boulard

Thornton

Franchini

Szabady

. (2013) Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210: 917–931.

43.

Klimesova

Kverka

Zakostelska

Hudcovic

Hrncir

Stepankova

. (2013) Altered gut microbiota promotes colitis-associated cancer in IL‑1 receptor-associated kinase M‑deficient mice. Inflamm Bowel Dis 19: 1266–1277.

44.

Korn

Bettelli

Oukka

Kuchroo

(2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485–517.

45.

Kosiewicz

Zirnheld

Alard

(2011) Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol 2: 180.

46.

Kostic

Chun

Robertson

Glickman

Gallini

Michaud

. (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14: 207–215.

47.

Koyama

Kagamu

Miura

Hiura

Miyabayashi

Itoh

. (2008) Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small-cell lung cancer reflects disease stage. Clin Cancer Res 14: 6770–6779.

48.

Kryczek

Banerjee

Cheng

Vatan

Szeliga

Wei

. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumour environments. Blood 114: 1141–1149.

49.

Kryczek

Wei

Zou

Altuwaijri

Szeliga

Kolls

. (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumour microenvironment. J Immunol 178: 6730–6733.

50.

Langowski

Zhang

Mattson

Chen

Smith

. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461–465.

51.

Lecuit

Lortholary

(2004) Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 350: 239–248.

52.

Lee

Rickman

Rogers

Wang

Fox

(2008) Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 68: 3540–3548.

53.

Liang

Tan

Luxenberg

Karim

Dunussi-Joannopoulos

Collins

. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271–2279.

54.

Lofgren

Whary

Muthupalani

Taylor

Mobley

. (2011) Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 140: 210–220.

55.

Mahowald

Rey

Seedorf

Turnbaugh

Fulton

Wollam

. (2009) Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 106: 5859.

56.

Mantovani

Allavena

Sica

Balkwill

(2008) Cancer-related inflammation. Nature 454: 436–444.

57.

Martin-Orozco

Muranski

Chung

Yang

Yamazaki

. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787–798.

58.

Mitsdoerffer

Lee

Jäger

Kim

Korn

Kolls

. (2010) Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA 107: 14292–14297.

59.

Munari

Fassan

Capitani

Codolo

Vila-Caballer

Pizzi

. (2014) Cytokine BAFF released by Helicobacter pylori-infected macrophages triggers the Th17response in human chronic gastritis. J Immunol 193: 5584–5594.

60.

Munari

Lonardi

Cassatella

Doglioni

Cangi

Amedei

. (2011) Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood Jun 117: 6612–6616.

61.

Muranski

Boni

Antony

Cassard

Irvine

Kaiser

. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362–373.

62.

Murugaiyan

Saha

(2009) Protumor vs antitumor functions of IL-17. J Immunol 183: 4169–4175.

63.

Numasaki

Fukushi

Ono

Narula

Zavodny

Kudo

. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620–2627.

64.

Ouyang

Kolls

Zheng

(2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454–467.

65.

Parkin

Bray

Ferlay

Pisani

(2002) Global cancer statistics. CA Cancer J Clin 55: 74–108.

66.

Peek

Blaser

(2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer 2: 28–37.

67.

Raffatellu

Santos

Verhoeven

George

Wilson

Winter

. (2008) Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 14: 421–428.

68.

Rakoff-Nahoum

Medzhitov

(2008) Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 73: 555–561.

69.

Reddy

Narisawa

Maronpot

Weisburger

Wynder

(1975) Animal models for the study of dietary factors and cancer of the large bowel. Cancer Res 35: 3421–3426.

70.

Reigstad

Backhed

(2010) Microbial regulation of SAA3 expression in mouse colon and adipose tissue. Gut Microbes 1: 55–57.

71.

Round

Lee

Tran

Jabri

Chatila

. (2011) The Toll-Like Receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332: 974–977.

72.

Rubinstein

Wang

Liu

Hao

Han

(2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14: 195–206.

73.

Russell

(1890). An address on a characteristic organism of cancer. Brit Med J 2: 1356–1360.

74.

Sacksteder

(1976) Occurrence of spontaneous tumors in the germfree F344 rat. J Natl Cancer Inst 57: 1371–1373.

75.

Schreiber

Old

Smyth

(2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570.

76.

Schwabe

Jobin

(2013) The microbiome and cancer Nature Reviews Cancer 13: 800–812.

77.

Sears

Pardoll

(2011) Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 203: 306–311.

78.

Shahanavaj

Gil-Bazo

Castiglia

Bronte

Passiglia

Carreca

. (2015) Cancer and the microbiome: potential applications as new tumor biomarker. Expert Rev Anticancer Ther 15: 317–330.

79.

Shaw

Kamada

Kim

Núñez

(2012) Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med 209: 251–258.

80.

Smith

Yatsunenko

Manary

Trehan

Mkakosya

Cheng

. (2013) Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339: 548–554.

81.

Sonnenburg

Angenent

Gordon

(2004) Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 5: 569–573.

82.

Starnes

(1992) Coley’s toxins in perspective. Nature 357: 11–12.

83.

Suzuki

Meek

Doi

Muramatsu

Chiba

Honjo

. (2004) Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Nat Acad Sci USA 101(7): 1981–1986.

84.

Thompson

Plummer

Tucker

Casey

(2010) Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 21: 1165–1170.

85.

Tjalsma

Boleij

Marchesi

Dutilh

(2012) A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 10: 575–582.

86.

Turnbaugh

Ley

Mahowald

Magrini

Mardis

Gordon

(2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.

87.

Vannucci

Stepankova

Kozakova

Fiserova

Rossmann

Tlaskalova-Hogenova

(2008) Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol 32: 609–617.

88.

Viaud

Saccheri

Mignot

Yamazaki

Daillère

Hannani

. (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342: 971–976.

89.

Wang

Edington

Rao

Jukic

Radfar

Wang

. (2008) Effects of high-dose IFNα2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 14: 8314–8320.

90.

Wang

Huycke

(2007). Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132: 551–561.

91.

Wang

Yang

Moore

Nimmo

Lightfoot

Huycke

(2012) 4‑Hydroxy-2‑nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology 142: 543–551.

92.

Welton

Marr

Friedman

(1979) Association between hepatobiliary cancer and typhoid carrier state. Lancet 1: 791–794.

93.

Wilke

Kryczek

Wei

Zhao

Wang

. (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32: 643–649.

94.

Wong

Lam

Wong

Chen

Zheng

Feng

. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187–194.

95.

Wotherspoon

Doglioni

Diss

Pan

Moschini

de Boni

. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–577.

96.

Rhee

Albesiano

Rabizadeh

Yen

. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med 15: 1016–1022.

97.

Yang

Novak

Ziesmer

Witzig

Ansell

(2019) Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res 69: 5522–5530.

98.

Yoshimoto

Loo

Atarashi

Kanda

Sato

Oyadomari

. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499: 97–101.

99.

Zhan

Chen

Sadler

Wang

Poe

Núñez

. (2013) Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res 73: 7199–7210.

100.

Zhang

Rong

Wei

Zhang

. (2008a) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533–537.

101.

Zhang

Yan

Pang

Chen

. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980–989.

102.

Zhang

Chen

Wei

Zheng

Sun

Zhang

. (2008b). Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432–6439.

103.

Zheng

Valdez

Danilenko

Gong

. (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine 14: 282–289.

104.

Ziesché

Bachmann

Kleinert

Pfeilschifter

Mühl

(2007) The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282: 16006–16015.

The interplay between the microbiome and the adaptive immune response in cancer development

Abstract

Keywords

Introduction

Microbiome’s role in tumor development

The role of adaptive immune response in cancer progression

Direct responsibility of bacterial factors in cancerogenesis

Antibacteria-specific immune response and tumor starting

Antitumorigenic impact of microbiome

Conclusion

Footnotes

Funding

Conflict of interest statement

References